Intec Parent Inc (NTEC) Stock Price & Overview
NASDAQ:NTEC
Current stock price
The current stock price of NTEC is 9.63 null. Today NTEC is down by -12.48%. In the past month the price decreased by -27.7%. In the past year, price decreased by -71.32%.
NTEC Key Statistics
- Market Cap
- 8.648M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.44
- Dividend Yield
- N/A
NTEC Stock Performance
NTEC Stock Chart
NTEC Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to NTEC. When comparing the yearly performance of all stocks, NTEC is a bad performer in the overall market: 98.9% of all stocks are doing better.
NTEC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NTEC. NTEC has a bad profitability rating. Also its financial health evaluation is rather negative.
NTEC Earnings
NTEC Forecast & Estimates
3 analysts have analysed NTEC and the average price target is 53.04 null. This implies a price increase of 450.78% is expected in the next year compared to the current price of 9.63.
NTEC Groups
Sector & Classification
NTEC Financial Highlights
Over the last trailing twelve months NTEC reported a non-GAAP Earnings per Share(EPS) of -3.44. The EPS increased by 80.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -83.12% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
NTEC Ownership
NTEC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.11 | 370.255B | ||
| AMGN | AMGEN INC | 15.28 | 188.011B | ||
| GILD | GILEAD SCIENCES INC | 15.19 | 166.661B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.34 | 110.013B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.78 | 77.991B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.53 | 42.088B | ||
| INSM | INSMED INC | N/A | 31.319B | ||
| BIIB | BIOGEN INC | 11.43 | 26.98B | ||
| NTRA | NATERA INC | N/A | 25.887B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.5 | 22.916B | ||
| MRNA | MODERNA INC | N/A | 19.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.333B | ||
| INCY | INCYTE CORP | 11.79 | 17.971B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NTEC
Company Profile
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. The company is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The firm is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
Company Info
IPO: 2015-07-30
Intec Parent Inc
12 Hartom Street, Har Hotzvim
JERUSALEM 777512 IL
CEO: Jeffrey A. Meckler
Employees: 70
Phone: 97225864657.0
Intec Parent Inc / NTEC FAQ
What does NTEC do?
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. The company is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The firm is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
What is the stock price of Intec Parent Inc today?
The current stock price of NTEC is 9.63 null. The price decreased by -12.48% in the last trading session.
What is the dividend status of Intec Parent Inc?
NTEC does not pay a dividend.
How is the ChartMill rating for Intec Parent Inc?
NTEC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for NTEC stock?
Intec Parent Inc (NTEC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.44).
What is the employee count for NTEC stock?
Intec Parent Inc (NTEC) currently has 70 employees.